The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
An article from
Dive Brief
//
Emerging biotech
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T
Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals - Johnson & Johnson
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline - Johnson & Johnson
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3
J&J pays $785M upfront to partner with Flagship's Sail Biomedicines on in vivo CAR-T for autoimmune diseases, with option to…
Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T
Johnson & Johnson expands its biotech pipeline with Firefly Bio acquisition and a strategic partnership with Sail Biomedicines.
Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.
Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a…
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly…
